An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation

Europace

Volumn 16, Issue 8, 2014, Pages 1117-1124

  Hohnloser, Stefan H ^a   Connolly, Stuart J ^b   John Camm, A ^c   Halperin, Jonathan L ^d   Radzik, David ^e  

^a GOETHE UNIVERSITY   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e SANOFI   (France)

Author keywords

Atrial fibrillation; Dronedarone; Randomized clinical trials

Indexed keywords

DIGOXIN; DRONEDARONE; PLACEBO; AMIODARONE; ANTIARRHYTHMIC AGENT;

ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMANS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84902101543     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu065     Document Type: Article

References (11)

1. SunW, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 2002;39:677-84.
2. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
3. Connolly SJ,CammAJ, Halperin JL, Joyner C, Alings M, Amerena J et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.
4. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354: 1896-900.
5. Touboul P, Brugada J, CapucciA, Crijns HJ, Edvardsson N,Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003;24: 1481-7.
6. Singh BN,Connolly SJ,CrijnsHJ, Roy D, Kowey PR,CapucciAet al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl JMed 2007; 357:987-99.
7. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527. e1.
8. Køber L, Torp-Pedersen C,McMurray JJ, Gøtzsche O, Levy S, CrijnsHet al. Increased mortality after dronedarone therapy for severe heart failure.NEngl J Med 2008;358: 2678-87.
9. Julious SA, Whitehead A. Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis. Pharm Stat 2012;11: 49-56. doi:10.1002/pst.494. Epub 2011 Dec 2.
10. Galbraith RF. Graphical display of estimates having differing standard errors. Technometrics 1988;30:271-281.
11. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012;110:607-13.